The House Oversight Committee released a report this week criticizing drugmakers’ stock buybacks, finding that 14 large pharmaceutical companies spent roughly $577 billion on such buybacks and dividends from 2016 to 2020.
House Oversight Committee criticizes drugmaker stock buybacks; says Medicare should have negotiating power
